ArticleInternational journal of molecular sciences2016
Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer.
Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Mass spectrometry-based serum peptidomic profiling reveals potential biomarker for canine hepatozoonosis.Scientific reports · 2025Article
- Amino Acid Profiling Identifies Disease-Specific Signatures in IgE-Mediated and Non-IgE-Mediated Food Allergy in Pediatric Patients with Atopic Dermatitis.Biomedicines · 2023Article
- Changes in Serum Protein-Peptide Patterns in Atopic Children Allergic to Plant Storage Proteins.International journal of molecular sciences · 2023Article
- Revealing the Hidden Diagnostic Clues of Male Infertility from Human Seminal Plasma by Dispersive Solid Phase Extraction and MALDI-TOF MS.International journal of molecular sciences · 2022Article
- Article
- Maternal serum proteomic profiles of pregnant women with type 1 diabetes.Scientific reports · 2022Article
- MALDI-TOF-MS analysis in low molecular weight serum peptidome biomarkers for NSCLC.Journal of clinical laboratory analysis · 2022Article
- Association between Venom Immunotherapy and Changes in Serum Protein-Peptide Patterns.Vaccines · 2021Article
- Rapid identification of novel independent serum biomarkers in diffuse large B-cell lymphoma.Translational cancer research · 2020Article
- Bioinformatic Analysis of the Wound Peptidome Reveals Potential Biomarkers and Antimicrobial Peptides.Frontiers in immunology · 2020Article
- Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.Immunogenetics · 2019Review
- Proteomic features characterization ofAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2019Article
- MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.BMC cancer · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to high mortality rates of lung cancer, there is a need for identification of new, clinically useful markers, which improve detection of this tumor in early stage of disease. In the current study, serum peptide profiling was evaluated as a diagnostic tool for non-small cell lung cancer patients. The combination of the ZipTip technology with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for the analysis of peptide pattern of cancer patients (n = 153) and control subjects (n = 63) was presented for the first time. Based on the observed significant differences between cancer patients and control subjects, the classification model was created, which allowed for accurate group discrimination. The model turned out to be robust enough to discriminate a new validation set of samples with satisfactory sensitivity and specificity. Two peptides from the diagnostic pattern for non-small cell lung cancer (NSCLC) were identified as fragments of C3 and fibrinogen α chain. Since ELISA test did not confirm significant differences in the expression of complement component C3, further study will involve a quantitative approach to prove clinical utility of the other proteins from the proposed multi-peptide cancer signature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.